Stay updated with breaking news from Pneumococcal Diseases. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases Results build on the data supporting the clinical profile...
MRK earnings call for the period ending March 31, 2024.
MRK earnings call for the period ending March 31, 2024.
Merck's V116, a 21-valent pneumococcal vaccine, exhibits strong immunogenicity and coverage in diverse adult populations. Real-world data reveal its potential to combat pneumococcal diseases effectively.
/PRNewswire/ -- According to a recent market study published by Growth Market Reports, titled, "Global Pediatric Epiphysiodesis Market Segments - by Technique...